• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

两性霉素B纳米脂质体制剂(西娜两性霉素)在动物模型中作为皮肤利什曼病治疗候选药物的安全性评价

Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (Sina Ampholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis.

作者信息

Eskandari Seyed Ebrahim, Firooz Alireza, Nassiri-Kashani Mansour, Jaafari Mahmoud Reza, Javadi Amir, Miramin-Mohammadi Akram, Valian-Keshavarz Hossein, Khamesipour Ali

机构信息

Center for Research and Training in Skin Diseases and Leprosy (CRTSDL), Tehran University of Medical Sciences, Tehran, Iran.

Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

J Arthropod Borne Dis. 2018 Sep 30;12(3):269-275. eCollection 2018 Sep.

PMID:30584550
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6297728/
Abstract

BACKGROUND

Development of a topical treatment for cutaneous leishmaniasis (CL) is an important step in the improvement of lesion management. Amphotericin B (AmB) is effective against species but it is toxic, a Nano-liposomal form of AmB with a size of about 100nm (Lip-AmB) was developed and showed to be effective against , and and against in animal model. This study was designed to check the irritancy Draize test in rabbits and was completed in the Center for Research and Training in Skin Diseases and Leprosy, TUMS, in 2012.

METHODS

Twenty rabbits in 3 steps were housed individually with artificial lighting (12/12h light/dark). SinaAmpholeish cream or empty liposomes (prepared under GMP condition at Minoo Company, Tehran, Iran), was applied on a gauze patch and the patches were placed on the designated sites of the skin in the back of the rabbits. At 48 and 72h later, the erythema and oedema were checked, scored and recorded.

RESULTS

The erythema score in rabbits was 0.83+0.41 for the SinaAmpholeish and 0.5+0.55 for empty liposomes (P= 0.16). The average score for oedema was 0.67+0.52 for SinaAmpholeish and 0.33+0.52 for empty liposomes (P= 0.16).

CONCLUSION

Based on skin irritancy reactions the topical formulation of SinaAmpholeish is safe and could be further checked in human trials.

摘要

背景

开发一种用于皮肤利什曼病(CL)的局部治疗方法是改善病损管理的重要一步。两性霉素B(AmB)对多种利什曼原虫有效,但具有毒性。已开发出一种大小约为100纳米的纳米脂质体形式的AmB(脂质体两性霉素B,Lip-AmB),并在动物模型中显示对多种利什曼原虫有效。本研究旨在通过家兔皮肤刺激试验(Draize试验)进行检验,并于2012年在德黑兰医科大学皮肤病与麻风病研究与培训中心完成。

方法

20只家兔分3个步骤单独饲养,采用人工照明(12小时光照/12小时黑暗)。将SinaAmpholeish乳膏或空脂质体(在伊朗德黑兰米诺公司按照药品生产质量管理规范条件制备)涂抹在纱布贴片上,然后将贴片放置在家兔背部皮肤的指定部位。在48小时和72小时后,检查、评分并记录红斑和水肿情况。

结果

家兔使用SinaAmpholeish后的红斑评分为0.83±0.41,使用空脂质体后的红斑评分为0.5±0.55(P = 0.16)。SinaAmpholeish的水肿平均评分为0.67±0.52,空脂质体的水肿平均评分为0.33±0.52(P = 0.16)。

结论

基于皮肤刺激反应,SinaAmpholeish的局部制剂是安全的,可在人体试验中进一步检验。

相似文献

1
Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (Sina Ampholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis.两性霉素B纳米脂质体制剂(西娜两性霉素)在动物模型中作为皮肤利什曼病治疗候选药物的安全性评价
J Arthropod Borne Dis. 2018 Sep 30;12(3):269-275. eCollection 2018 Sep.
2
Field Efficacy of Topical Nano-Liposomal Amphotericin B (Sina Ampholeish®) Alone or in Combination with Glucantime® and Cryotherapy on Human Cutaneous Leishmaniasis.局部应用纳米脂质体两性霉素B(Sina Ampholeish®)单独或与戊烷脒(Glucantime®)及冷冻疗法联合治疗人类皮肤利什曼病的现场疗效
Iran J Parasitol. 2023 Oct-Dec;18(4):419-426. doi: 10.18502/ijpa.v18i4.14241.
3
Safety Evaluation of Topical Application of Nano-Liposomal Form of Amphotericin B (SinaAmpholeish) on Healthy Volunteers: Phase I Clinical Trial.两性霉素B纳米脂质体剂型(SinaAmpholeish)局部应用于健康志愿者的安全性评估:I期临床试验
Iran J Parasitol. 2019 Apr-Jun;14(2):197-203.
4
Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.开发一种局部的两性霉素 B 脂质体制剂,用于治疗皮肤利什曼病。
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:156-165. doi: 10.1016/j.ijpddr.2019.09.004. Epub 2019 Sep 23.
5
Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by : study protocol for a randomized, controlled trial.局部用两性霉素B脂质体与葡聚糖铁组合与单独使用葡聚糖铁治疗由……引起的人源性皮肤利什曼病(ACL)的比较:一项随机对照试验的研究方案
Iran J Microbiol. 2021 Oct;13(5):718-723. doi: 10.18502/ijm.v13i5.7440.
6
Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes.两性霉素B聚乙二醇化脂质体的制剂,用于通过肠胃外和口服途径改善皮肤利什曼病的治疗。
Pharmaceutics. 2022 May 5;14(5):989. doi: 10.3390/pharmaceutics14050989.
7
Biodistribution and Antileishmanial Activity of 1,2-Distigmasterylhemisuccinoyl--Glycero-3-Phosphocholine Liposome-Intercalated Amphotericin B.1,2-二油酰基-琥珀酰基-β-甘油磷酰胆碱脂质体插层两性霉素 B 的体内分布和抗利什曼原虫活性。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.02525-16. Print 2017 Sep.
8
Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.新型两性霉素 B-米替福新共包封第二代超变形脂质体局部治疗皮肤利什曼病。
Int J Pharm. 2020 Jan 5;573:118900. doi: 10.1016/j.ijpharm.2019.118900. Epub 2019 Nov 22.
9
The activity of encapsulated meglumine antimoniate in stearylamine-bearing liposomes against cutaneous leishmaniasis in BALB/c mice.含硬脂胺脂质体包裹的葡甲胺锑酸盐对BALB/c小鼠皮肤利什曼病的活性
Exp Parasitol. 2019 May;200:30-35. doi: 10.1016/j.exppara.2019.03.004. Epub 2019 Mar 18.
10
Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica.脂质体两性霉素 B 治疗热带利什曼原虫引起的皮肤利什曼病。
J Eur Acad Dermatol Venereol. 2011 Aug;25(8):973-7. doi: 10.1111/j.1468-3083.2010.03908.x. Epub 2010 Dec 5.

引用本文的文献

1
Field Efficacy of Topical Nano-Liposomal Amphotericin B (Sina Ampholeish®) Alone or in Combination with Glucantime® and Cryotherapy on Human Cutaneous Leishmaniasis.局部应用纳米脂质体两性霉素B(Sina Ampholeish®)单独或与戊烷脒(Glucantime®)及冷冻疗法联合治疗人类皮肤利什曼病的现场疗效
Iran J Parasitol. 2023 Oct-Dec;18(4):419-426. doi: 10.18502/ijpa.v18i4.14241.
2
Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations.脂质体两性霉素B治疗利什曼病:从关键物理化学特性的鉴定到有效局部和口服制剂的设计
Pharmaceutics. 2022 Dec 28;15(1):99. doi: 10.3390/pharmaceutics15010099.
3

本文引用的文献

1
Therapeutic vaccines for leishmaniasis.用于利什曼病的治疗性疫苗。
Expert Opin Biol Ther. 2014 Nov;14(11):1641-9. doi: 10.1517/14712598.2014.945415. Epub 2014 Jul 31.
2
Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.使用含葡甲胺锑酸盐(葡糖胺锑)的局部脂质体治疗BALB/c小鼠的硕大利什曼原虫损伤。
Exp Parasitol. 2014 Aug;143:5-10. doi: 10.1016/j.exppara.2014.04.013. Epub 2014 Apr 26.
3
Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach.
Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL) caused by : study protocol for a randomized, controlled trial.
局部用两性霉素B脂质体与葡聚糖铁组合与单独使用葡聚糖铁治疗由……引起的人源性皮肤利什曼病(ACL)的比较:一项随机对照试验的研究方案
Iran J Microbiol. 2021 Oct;13(5):718-723. doi: 10.18502/ijm.v13i5.7440.
4
Evaluation of a New Topical Treatment for the Control of Cutaneous Leishmaniasis.一种用于控制皮肤利什曼病的新型局部治疗方法的评估。
Microorganisms. 2020 Nov 17;8(11):1803. doi: 10.3390/microorganisms8111803.
5
Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.开发一种局部的两性霉素 B 脂质体制剂,用于治疗皮肤利什曼病。
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:156-165. doi: 10.1016/j.ijpddr.2019.09.004. Epub 2019 Sep 23.
6
Safety Evaluation of Topical Application of Nano-Liposomal Form of Amphotericin B (SinaAmpholeish) on Healthy Volunteers: Phase I Clinical Trial.两性霉素B纳米脂质体剂型(SinaAmpholeish)局部应用于健康志愿者的安全性评估:I期临床试验
Iran J Parasitol. 2019 Apr-Jun;14(2):197-203.
通过 cDNA-AFLP 方法鉴定热带利什曼原虫田间分离株中的抗锑标记。
Exp Parasitol. 2013 Oct;135(2):344-9. doi: 10.1016/j.exppara.2013.07.018. Epub 2013 Aug 6.
4
Leishmaniasis worldwide and global estimates of its incidence.全球利什曼病及其发病率的全球估计。
PLoS One. 2012;7(5):e35671. doi: 10.1371/journal.pone.0035671. Epub 2012 May 31.
5
Treatment of cutaneous lesion of 20 years' duration caused by leishmanization.治疗由利什曼化引起的病程20年的皮肤病变。
Indian J Dermatol. 2012 Mar;57(2):123-5. doi: 10.4103/0019-5154.94280.
6
Leishmaniasis chemotherapy--challenges and opportunities.利什曼病化疗——挑战与机遇。
Clin Microbiol Infect. 2011 Oct;17(10):1478-83. doi: 10.1111/j.1469-0691.2011.03630.x.
7
Alternative methods for eye and skin irritation tests: an overview.眼和皮肤刺激试验的替代方法:综述
J Pharm Sci. 2008 Jan;97(1):46-59. doi: 10.1002/jps.21088.
8
Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials.急性旧大陆皮肤利什曼病的治疗:随机对照试验的系统评价
J Am Acad Dermatol. 2007 Aug;57(2):335.e1-29. doi: 10.1016/j.jaad.2007.01.016. Epub 2007 Mar 6.
9
Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.咪喹莫特联合葡甲胺锑酸盐治疗皮肤利什曼病:一项随机、评估者盲法对照试验。
Arch Dermatol. 2006 Dec;142(12):1575-9. doi: 10.1001/archderm.142.12.1575.
10
Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.由于耐药性热带利什曼原虫寄生虫,伊朗皮肤利什曼病对葡糖胺锑治疗无反应。
PLoS Med. 2006 May;3(5):e162. doi: 10.1371/journal.pmed.0030162. Epub 2006 Apr 18.